TriangleNCT02366143 · OUTCOME
Percentage of Participants With an Objective Response (OR) (Complete Response [CR] or Partial Response [PR]) as Determined by the Investigator in the Teff-High-WT Population and ITT-WT Population
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- Percentage
- Interval / dispersion
- Not reported
- Time frame
- Baseline until disease progression or death, whichever occurs first (up to approximately 29 months)
What was measured
Percentage of Participants With an Objective Response (OR) (Complete Response \[CR\] or Partial Response \[PR\]) as Determined by the Investigator using RECIST v1.1 in the Teff-High-WT population and ITT-WT population.
Analysis population: Teff-high WT population is defined as the Teff-high population excluding patients with an activating EGFR mutation or ALK translocation. ITT-WT population is defined as the ITT population excluding patients with an activating EGFR mutation or ALK translocation.
Groups in this outcome
Arm A (Atezolizumab+Paclitaxel+Carboplatin)
Participants received intravenous (IV) infusion of atezolizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.
Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)
Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.
Arm C (Bevacizumab+Paclitaxel+Carboplatin)
Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.
| Group | Source count |
|---|---|
| Arm A (Atezolizumab+Paclitaxel+Carboplatin) | 347 |
| Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) | 353 |
| Arm C (Bevacizumab+Paclitaxel+Carboplatin) | 331 |
Reported measurements
Teff-high WT Population
| Group | Source count |
|---|---|
| Arm A (Atezolizumab+Paclitaxel+Carboplatin) | 161 |
| Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) | 153 |
| Arm C (Bevacizumab+Paclitaxel+Carboplatin) | 127 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Arm A (Atezolizumab+Paclitaxel+Carboplatin) | 54.0 | Not reported | Not reported | Not reported | Not reported |
| Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) | 69.3 | Not reported | Not reported | Not reported | Not reported |
| Arm C (Bevacizumab+Paclitaxel+Carboplatin) | 53.5 | Not reported | Not reported | Not reported | Not reported |
ITT-WT Population
| Group | Source count |
|---|---|
| Arm A (Atezolizumab+Paclitaxel+Carboplatin) | 347 |
| Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) | 353 |
| Arm C (Bevacizumab+Paclitaxel+Carboplatin) | 331 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Arm A (Atezolizumab+Paclitaxel+Carboplatin) | 49.3 | Not reported | Not reported | Not reported | Not reported |
| Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) | 63.5 | Not reported | Not reported | Not reported | Not reported |
| Arm C (Bevacizumab+Paclitaxel+Carboplatin) | 48.0 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 54.0
- group Id
- OG001
- value
- 69.3
- group Id
- OG002
- value
- 53.5
- denoms
- counts
- group Id
- OG000
- value
- 161
- group Id
- OG001
- value
- 153
- group Id
- OG002
- value
- 127
- units
- Participants
- title
- Teff-high WT Population
- categories
- measurements
- group Id
- OG000
- value
- 49.3
- group Id
- OG001
- value
- 63.5
- group Id
- OG002
- value
- 48.0
- denoms
- counts
- group Id
- OG000
- value
- 347
- group Id
- OG001
- value
- 353
- group Id
- OG002
- value
- 331
- units
- Participants
- title
- ITT-WT Population
- denoms
- counts
- group Id
- OG000
- value
- 347
- group Id
- OG001
- value
- 353
- group Id
- OG002
- value
- 331
- units
- Participants
- description
- Percentage of Participants With an Objective Response (OR) (Complete Response \[CR\] or Partial Response \[PR\]) as Determined by the Investigator using RECIST v1.1 in the Teff-High-WT population and ITT-WT population.
- groups
- description
- Participants received intravenous (IV) infusion of atezolizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.
- id
- OG000
- title
- Arm A (Atezolizumab+Paclitaxel+Carboplatin)
- description
- Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.
- id
- OG001
- title
- Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)
- description
- Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.
- id
- OG002
- title
- Arm C (Bevacizumab+Paclitaxel+Carboplatin)
- param Type
- NUMBER
- population Description
- Teff-high WT population is defined as the Teff-high population excluding patients with an activating EGFR mutation or ALK translocation. ITT-WT population is defined as the ITT population excluding patients with an activating EGFR mutation or ALK translocation.
- reporting Status
- POSTED
- time Frame
- Baseline until disease progression or death, whichever occurs first (up to approximately 29 months)
- title
- Percentage of Participants With an Objective Response (OR) (Complete Response [CR] or Partial Response [PR]) as Determined by the Investigator in the Teff-High-WT Population and ITT-WT Population
- type
- SECONDARY
- unit Of Measure
- Percentage
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice